SWOG 1612 A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial)

October 22, 2018
https://clinicaltrials.gov/ct2/show/NCT03092674
Cancer - Hematology/ Blood, Cancer - Leukemia
Principal Investigator: Ding Wang, MD
MDS, AML, LEUKEMIA, MYELODYSPLASTIC SYNDROME
Open